Count | |
2 | |
3 | |
1 | |
1 | |
Antiparkinson Agents/administration & dosage/blood/*pharmacokinetics | 2 |
Antiparkinson Agents/*administration & dosage/adverse effects | 2 |
3 | |
1 | |
1 | |
7 | |
13 | |
7 | |
2 | |
1 | |
1 | |
1 | |
1 | |
2 | |
1 | |
1 | |
1 | |
1 | |
2 | |
1 | |
1 | |
1 | |
1 | |
1 | |
1 | |
1 | |
1 | |
1 | |
Antiparkinson Agents/pharmacokinetics/pharmacology/*therapeutic use | 1 |
1 | |
1 | |
3 | |
2 | |
Antiparkinson Agents/adverse effects/*pharmacology/therapeutic use | 1 |
Antiparkinson Agents/adverse effects/*pharmacokinetics/*therapeutic use | 1 |
Antiparkinson Agents/adverse effects/pharmacokinetics/*therapeutic use | 1 |
Antiparkinson Agents/*adverse effects/blood/*therapeutic use | 1 |
Antiparkinson Agents/adverse effects/pharmacokinetics/*pharmacology | 1 |
Antiparkinson Agents/adverse effects/*pharmacokinetics/therapeutic use | 1 |
1 | |
2 | |
5 | |
30 | |
6 | |
1 | |
1 | |
3 | |
11 | |
2 | |
2 | |
1 | |
1 | |
12 | |
5 | |
2 | |
1 | |
1 | |
10 | |
9 | |
29 | |
26 | |
1 | |
6 | |
6 | |
10 | |
11 | |
2 | |
1 | |
2 | |
1 | |
2 | |
1 | |
2 | |
6 | |
1 | |
1 | |
6 | |
1 | |
1 | |
66 | |
1 | |
1 | |
2 | |
2 | |
3 | |
4 | |
1 | |
14 | |
3 | |
1 | |
1 | |
10 | |
6 | |
58 | |
7 | |
9 | |